Trevena (NASDAQ:TRVN) Now Covered by StockNews.com

Posted by on May 17th, 2023

Stock analysts at StockNews.com began coverage on shares of Trevena (NASDAQ:TRVN – Get Rating) in a research report issued on Wednesday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Several other brokerages have also recently weighed in on TRVN. HC Wainwright reduced their price objective on Trevena from $11.00 to $9.00 and set a “buy” rating on the stock in a research note on Friday, March 31st. JMP Securities reissued a “market outperform” rating and set a $2.00 price objective on shares of Trevena in a research note on Friday, March 31st.

Trevena Trading Up 6.4 %

Shares of TRVN stock opened at $1.26 on Wednesday. Trevena has a 12-month low of $0.58 and a 12-month high of $12.22. The company has a current ratio of 4.70, a quick ratio of 4.59 and a debt-to-equity ratio of 0.86. The stock’s 50-day moving average price is $0.87 and its 200-day moving average price is $1.71. The stock has a market capitalization of $12.04 million, a price-to-earnings ratio of -0.16 and a beta of 2.05.

Trevena (NASDAQ:TRVN – Get Rating) last issued its earnings results on Monday, May 15th. The biopharmaceutical company reported ($0.81) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.85) by $0.04. The firm had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.60 million. During the same period last year, the firm posted ($2.50) earnings per share. Equities research analysts predict that Trevena will post -3.03 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Dimensional Fund Advisors LP bought a new position in shares of Trevena during the fourth quarter valued at approximately $40,000. Jane Street Group LLC grew its stake in shares of Trevena by 166.2% during the first quarter. Jane Street Group LLC now owns 45,330 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 28,303 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Trevena by 51.8% in the first quarter. Renaissance Technologies LLC now owns 70,532 shares of the biopharmaceutical company’s stock valued at $49,000 after purchasing an additional 24,080 shares during the period. Virtu Financial LLC purchased a new stake in shares of Trevena in the second quarter valued at approximately $70,000. Finally, Captrust Financial Advisors boosted its holdings in shares of Trevena by 10,526.3% in the first quarter. Captrust Financial Advisors now owns 201,900 shares of the biopharmaceutical company’s stock valued at $111,000 after purchasing an additional 200,000 shares during the period.

Trevena Company Profile

(Get Rating)

Trevena, Inc is a biopharmaceutical company, which focuses on developing and commercializing novel medicines for patients affected by central nervous system, or CNS, disorders. Its product candidates include Oliceridine injection, TRV250, TRV734, and TRV045. The company was founded by Maxine Gowen, Robert Joseph Lefkowitz, Scott DeWire, Howard A.

Read More

Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.